NCMAG117 Dasatinib advice document: July 2024

Posted on:


Document Type

NCMAG advice

Process guidance

Summary

For the treatment of adult patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukaemia with resistance or intolerance to prior therapy. (On-label use and off-patent medicine.)

Decision: supported